Inactive Instrument

Fresenius Kabi Oncology Ltd Share Price

Equities

End-of-day quote NSE India S.E. Other stock markets
- ^INR	-

2016	AstraZeneca sells rights to anaesthetics for up to $770 million	RE
2015	Fresenius SE KGaA : Kabi sells German oncology compounding business	RE

AstraZeneca sells rights to anaesthetics for up to $770 million	09/16/09	RE
Fresenius SE KGaA : Kabi sells German oncology compounding business	16/15/16	RE
Fresenius Kabi Oncology Ltd : India revokes GSK cancer drug patent in latest Big Pharma blow	02/13/02	RE
Fresenius Kabi Oncology Ltd : India board revokes GSK patent on breast cancer drug Tykerb	02/13/02	RE

Managers	Title	Age	Since
Arvind Kumar Sharma CEO	Chief Executive Officer	-	01/18/01
Rahul Sharma DFI	Director of Finance/CFO	-	-
Maria Gobbi CHM	Chairman	-	13/14/13

Members of the board	Title	Age	Since
Michael Schönhofen BRD	Director/Board Member	63	11/08/11
Nikhil Kulshreshtha BRD	Director/Board Member	-	21/07/21
Maria Gobbi CHM	Chairman	-	13/14/13

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.22%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.97%	11TCr
BIONTECH SE	-13.57%	2.23TCr
ARGENX SE	-3.99%	2.16TCr
BEIGENE, LTD.	-5.79%	1.82TCr
WUXI APPTEC CO., LTD.	-39.93%	1.76TCr
NEUROCRINE BIOSCIENCES, INC.	+7.30%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+33.56%	1.24TCr
LEGEND BIOTECH CORPORATION	-28.05%	828.11Cr